At this year’s international hematology meeting, OPALE members are playing a prominent role in advancing acute myeloid leukemia (AML) and leukemia research, through a series of high-impact abstracts and oral presentations.
These contributions—spanning induction strategies, molecular relapse, targeted therapies, and clonal evolution—offer a clear illustration of what cohesive national research consortia can achieve when clinical expertise, biological insight, and methodological rigor converge.
Several studies presented today are the result of close collaboration between leading French organizations, including:
ALFA – Acute Leukemia French Association
FILO – French Innovative Leukemia Organization
Société Francophone de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)
Together, these groups form the backbone of a coordinated national ecosystem capable of generating robust, practice-shaping clinical evidence in leukemia.
OPALE congratulates Christian Recher and Mathilde Chanut, who opened the day with well-attended sessions reflecting both the scientific relevance and international visibility of French leukemia research.
9:30 AM – Valencia Room W415A | Paper No. 0043
Induction chemotherapy with a single anthracycline-containing cycle in younger adults with newly diagnosed AML
BIG-1 Study, on behalf of FILO, ALFA, and SFGM-TC
Presenter: Christian Recher
This study revisits the foundations of induction therapy, questioning long-established assumptions around anthracycline exposure in younger AML patients.
9:30 AM – Valencia Room W415BC | Paper No. 0037
Therapy-related CBF AML: a study of the French acute leukemia intergroup
Presenter: Mathilde Chanut
An important contribution addressing prognosis and biology in a rare but clinically challenging AML subset.
10:30 AM – Valencia Room W415D | Paper No. 0077
Molecular landscape and clonal evolution in minor versus major BCR::ABL1 CML under tyrosine kinase inhibition
Presenter: Benjamin Podvin
This study sheds light on clonal dynamics under targeted pressure—an issue increasingly relevant across myeloid malignancies.
2:00 PM – W414AB | Session 618
Acute Myeloid Leukemias – Biomarkers and Molecular Markers in Diagnosis and Prognosis
Session theme: Redefining AML through genetic, phenotypic, and response-based insights
Moderators: Raphael Itzykson & Rahul Vedula
This session underscores the shift from purely morphological classifications toward integrated, response-driven frameworks in AML.
5:00 PM – Valencia Room W415A | Paper No. 0347
Salvage strategies and outcomes in CBF- or NPM1-mutated AML at first molecular relapse
Presenter: Corentin Orvain
5:30 PM – West Halls B3–B4 | Paper No. 1682
Impact of midostaurin in younger AML patients treated with high-dose anthracycline
Presenter: Pierre-Yves Dumas
5:30 PM – West Halls B3–B4 | Paper No. 1658
Real-life use of ivosidenib alone or combined with azacitidine in first-line IDH1-mutated AML
Presenter: Pierre Peterlin
These presentations bridge controlled trial data with real-world practice, an increasingly critical dimension for regulators and clinicians alike.
Beyond the impressive number of abstracts (??) and presentations (??), a deeper message emerges:
scale, coordination, and methodological consistency are becoming decisive drivers of progress in leukemia research.
For OPALE, this reinforces a central conviction: the next breakthroughs in AML will not come from isolated innovation alone, but from collective intelligence applied rigorously at every stage of the trial continuum.